Menu
Annual · values202520242023202220212020
Operating Cash Flow-6.05 M USD-7.82 M USD-8.31 M USD-7.74 M USD-4.37 M USD-508710 USD
Depreciation & Amortization74182 USD75618 USD648708 USD156598 USD145719 USD157039 USD
Stock-Based Compensation6 USD20094 USD189245 USD433004 USD68458 USD3730 USD
Capital Expenditures173735 USD306783 USD704166 USD1.20 M USD23947 USD
Cash Flow from Investing-173735 USD-306783 USD-704166 USD-1.20 M USD-23947 USD
Cash Flow from Financing7.09 M USD10.22 M USD1.11 M USD8075 USD22.53 M USD1.33 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-6.23 M USD-8.13 M USD-9.02 M USD-8.94 M USD-4.39 M USD

Bluejay Diagnostics Inc. is a medical technology company focused on developing and marketing rapid diagnostic solutions for use in clinical settings. The company specializes in minimally invasive point-of-care tests and devices designed to provide timely, lab-quality biomarker results near the patient, supporting faster clinical decision-making in critical care environments. Its flagship Symphony platform is a near-patient biomarker detection system aimed at conditions where early and precise measurement of inflammatory and infectious markers can guide treatment. Bluejay Diagnostics primarily targets the infectious disease, inflammation, and oncology markets, working to enable more efficient triage and monitoring of patients in emergency departments, intensive care units, and other acute-care settings. Headquartered in Acton, Massachusetts and founded in 2015, the company operates within the health technology sector and the medical specialties industry, serving healthcare providers seeking to streamline workflows and improve access to actionable diagnostic information at or near the point of care.